Gastroenterologie
a hepatologie

Azathioprine in the therapy of paediatric inflammatory bowel disease – part I: treatment indications, dosing and thiopurine-related adverse events

Kristýna Pospíšilová¹, Jiří Bronský ^{Orcid.org  1}

+ Affiliation
¹ Oddělení dětské gastroenterologie, Pediatrická klinika 2. LF UK a FN Motol, Praha

Summary

Background: Thiopurines (in Europe mainly azathioprine) are widely used in the treatment of inflammatory bowel diseases in children. Due to a prolonged time until the onset of therapeutic effect, those drugs are aimed to be used in the maintenance phase of the therapy rather than for induction of remission. Thiopurines are sometimes used in combination therapy (with aminosalicylates or biological treatment agents). The adverse events of these drugs occur as often as in 15–40% cases and may lead to treatment cessation in a significant number of patients. Aims: To overview available information on (mainly) children suffering from inflammatory bowel disease. Conclusion: Genetic examination accompanied with laboratory monitoring of blood count parameters (specifically at the beginning of therapy) and biochemistry can help prevent some of the severe adverse events.

Keywords

Crohn’s disease, ulcerative colitis, pediatrie, merkaptopurin, thiopuriny

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Prefontaine E, Sutherland LR, MacDonald JK et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn‘s disease. Cochrane Database Syst Rev 2010; 1: CD000067. doi: 10.1002/14651858.CD000067.pub3.
2. Ramadas AV, Gunesh S, Thomas GA et al. Natural history of Crohn‘s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatement and surgical resection rates. Gut 2010; 59(9): 1200–1206. doi: 10.1136/gut.2009.202101.
3. Peyrin-Biroulet L, Oussalah A, Williet N et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly dia­gnosed Crohn‘s disease. Gut 2011; 60(7): 930–936. doi: 10.1136/gut.2010.227884.
4. Cleynen I, Ganzales JR, Figueroa C et al. Genetic factors conferring an increased susceptibility to develop Crohn‘s disease also influence disease phenotype: results from IBSchip European project. Gut 2013; 62(11): 1556–1565. doi: 10.1136/gutjnl-2011-300777.
5. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatement of inflammatory bowel disease: a 30 year review. Gut 2002; 50(4): 485–489. doi: 10.1136/gut.50.4.485.
6. Cosnes J, Bourier A, Laharie D et al. Early administration of azathioprine vs conventional management of Crohn‘s disease: a randomized controlled trial. Gastroenterol 2013; 145(4): 758–765. doi: 10.1053/j.gastro.2013.04.048.
7. Panés J, López-Sanromán A, Bermejo A et al. Early azathioprine therapy is no more effective than placebo for newly dia­gnosed Crohn‘s disease. Gastroenterol 2013; 145(4): 766–774. doi: 10.1053/j.gastro.2013.06.009.
8. Pearson DC, May GR, Fick GH et al. Azathioprine and 6-mercaptopurine in Crohn disease. Ann Intern Med 1995; 123(2): 132–142. doi: 10.7326/0003-4819-123-2-199507150-00009.
9. Markowitz J, Grancher K, Kohn N et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly dia­gnosed Crohn‘s disease. Gastroenterol 2000; 119(4): 895–902. doi: 10.1053/gast.2000.18144.
10. Barabino A, Torrente F, Ventura A et al. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther 2002; 16(6): 1125–1130. doi: 10.1046/j.1365-2036.2002.01269.x.
11. Punati J, Markowitz J, Lerer T et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis 2008; 14(7): 949–954. doi: 10.1002/ibd.20412.
12. Riello L, Talbotec C, Garnier-Lengliné H et al. Tolerance and efficacy of azathioprine in pediatric Crohn‘s disease. Inflamm Bowel Dis 2011; 17(10): 2138–2143. doi: 10.1002/ibd.21612.
13. Timmer A, Patton PH, Chande N et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; 2016(5): CD000478. doi: 10.1002/14651858.CD000478.pub4.
14. Gisbert JP, Nino P, Cara C et al. Comparative effectivenes of azathioprine in Crohn‘s disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther 2008; 28(2): 228–238. doi: 10.1111/j.1365-2036.2008.03732.x.
15. Verhave M, Winter HS, Grand RJ. Azathioprinein the treatement of children with inflammatory bowel disease. J Pediatr 1990; 117(5): 809–814. doi: 10.1016/s0022-3476 (05) 83349-9.
16. Kader HA, Mascarenhas MR, Piccoli DA et al. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. Gastroenterol Nutr 1999; 28(1): 54–58. doi: 10.1097/00005176-19 9901000-00013.
17. Hyams JS, Lerer T, Mack D et al. Outcome fol­lowing thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol 2011; 106(5): 981–987. doi: 10.1038/ajg.2010.493.
18. Khan N, Dubinsky MC, Ford AC et al. Efficacy of immunosuppresive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106(4): 630–642. doi: 10.1038/ajg.2011.64.
19. Ruemmelle FM, Veres G, Kolho KL et al. Consensus guidelines of ECCO/ESPHGAN on the medical management of pediatric Crohn‘s disease. J Crohns Colitis 2014; 8(10): 1179–1207. doi: 10.1016/j.crohns.2014.04.005.
20. Adamcová M, Bajer M, Bajerová K et al. Doporučení Pracovní skupiny dětské gastroenterologie a výživy ČPS pro dia­gnostiku a léčbu nespecifických střevních zánětů u dětí. Čes-slov Pediat 2012; 67(Suppl 2): S5–S47.
21. Bronský J, Beránková K, Černá Z et al. Doporučení Pracovní skupiny dětské gastroenterologie a výživy ČPS pro dia­gnostiku a léčbu nespecifických střevních zánětů u dětí – doplněk k 1. vydání. Gastroent Hepatol 2017; 71(1): 11–18. doi: 10.14735/amgh201711.
22. Turner D, Levine A, Escher JC et al. Management of pediatric ulcerative colitis: joint ECCO and ESPHGAN evedence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012; 55(3): 340–361. doi: 10.1097/MPG.0b013e3182662233.
23. Pozler O, Chládek J, Malý J et al. Steady-state of azathioprine during initiation treatement of pediatric inflammatory bowel disease. J Crohns Colitis 2010; 4(6): 623–628. doi: 10.1016/j.crohns.2010.06.005.
24. Louis E, Belaiche J. Optimizing treatement with thioguanine derivates in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003; 17(1): 37–46. doi: 10.1053/bega.2002.0346.
25. Turner D, Ruemmele FM, Orlanski-Meyer E et al. Management of paediatric ulcerative colitis, part 1: ambulatory care- an evidence-based guideline from ECCO and ESPGHAN. J Pediatr Gastroenterol Nutr 2018; 67(2): 257–291. doi: 10.1097/MPG.0000000000002035.
26. Van Os EC, J A McKinney JA, Zins BJ et al. Simultaneous determination of azathioprine and 6-mercaptopurine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996; 679(1–2): 147–154. doi: 10.1016/0378-4347(96)00007-2.
27. Hindorf U, Lindqvist M, Hildebrand H et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24(2): 331–342. doi: 10.1111/j.1365-2036.2006.02977.x.
28. Stocco G, Martelossi S, Arrigo S et al. Multicentric case-control study on azathioprine dose and pharmacokinetics in early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis 2017; 23(4): 628–634. doi: 10.1097/MIB.0000000000001051.
29. Grossman AB, Noble AJ, Mamula P et al. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis 2008; 14(6): 750–755. doi: 10.1002/ibd.20387.
30. Luan ZJ, Li Y, Zhao XY et al. Treatment efficacy and safety of low-dose azathioprine in chronic active ulcerative colitis patients: a meta-analysis and systemic review. J Dig Dis 2016; 17(10): 652–659. doi: 10.1111/1751-2980.12386.
31. Ansari A, Hassan C, Duley J et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16(10): 1743–1750. doi: 10.1046/j.1365-2036.2002.01353.x.
32. Schaeffeler E, Fisher C, Dierk B et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14(7): 407–417. doi: 10.1097/01.fpc.0000114745.08559.db.
33. Winter JW, Gaffney D, Shapiro D et al. Assesment of thiopurine methyltransferase nezyme activity is superior to genotpye in predicting myelosuppresion following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25(9): 1069–1077. doi: 10.1111/j.1365-2036.2007.03301.x.
34. Jones J, Kaplan GG, Peyrin-Biroulet L et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn‘s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2015; 13(13): 2233–2240. doi: 10.1016/j.cgh.2015.06.034.
35. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn‘s disease. N Engl J Med 2010; 362(15): 1383–1395. doi: 10.1056/NEJMoa0904492.
36. Panaccione R, Ghosh S, Middleton S et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. Gastroenterology 2011; 5(1): S8.
37. Van Assche G, Magdelaine-Beuzelin C, D‘Haens G et al. Withdrawal of immunosuppression in Crohn‘s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134(7): 1861–1868. doi: 10.1053/j.gastro.2008.03.004.
38. Kierkus J, Iwanczyk B, Wegner A et al. Efficacy infliximab with immunomodulator and infliximab alone of maintenance therapy in children with Crohn‘s disease – multicenter randomized study. J Crohns Colitis 2013; 7: 220–221.
39. Church PC, Hyams J, Ruemmele F et al. The continental divide anti-TNF use in pediatric IBD is different in North America compared to other parts of the world. Can J Gastroenterol Hepatol 2018; 2018: 3190548. doi: 10.1155/2018/3190548.
40. Pariente B, Laharie E. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2014; 40(4): 338–353. doi: 10.1111/apt.12838.
41. Ben-Horin S, Waterman M, Kopylov U et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11(4): 444–447. doi: 10.1016/j.cgh.2012.10.020.
42. Ungar B, Kopylov U, Engel T et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther 2017; 45(2): 276–282. doi: 10.1111/apt.13862.
43. Reenaers C, Louis E, Belaiche J et al. Does co-treatment with immunosuppressors improve outcome in patients with Crohn‘s disease treated with adalimumab? Aliment Pharmacol Ther 2012; 36(11–12): 1040–1048. doiI: 10.1111/apt.12076.
44. Matsumoto T, Motoya S, Watanabe K et al. Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: a prospective randomized trial. J Crohns Colitis 2016; 10(11): 1259–1266. doi: 10.1093/ecco-jcc/jjw152.
45. Dulai PS, Singh S, Jiang X et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn‘s disease: results from the US VICTORY consortium. Am J Gastroenterol 2016; 111(8): 1147–1155. doi: 10.1038/ajg.2016.236.
46. Shelton E, Allegretti JR, Stevens B et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis 2015; 21(12): 2879–2885. doi: 10.1097/MIB.0000000000000561.
47. Ledder O, Assa A, Levine A et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD Porto group of ESPGHAN. J Crohn Colitis 2017; 11(10): 1230–1237. doi: 10.1093/ecco-jcc/jjx082.
48. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterol 1998; 115(4): 813–821. doi: 10.1159/000140974.
49. Costantino G, Furfaro F, Belvedere A et al. Thiopurine treatement in inflammatory bowel disease: response predictors, safety, and witch­drawal in follow-up. J Crohns Colitis 2012; 6(5): 588–596. doi: 10.1016/j.crohns.2011.11.007.
50. Gearry RB, Barclay ML, Burt MJ et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004; 13(8): 563–567. doi: 10.1002/pds.926.
51. Qiu Y, Mao R, Zhang S et al. Safety profile of thiopurines in Crohn disease: analysis of 893 patient-years follow-up in a Southern China cohort. Medicine 2015; 94(41): e1513. doi: 10.1097/MD.0000000000001513.
52. Lopéz-Martín C, Chaparro M, Espinosa L et al. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. Gastroenterol Hepatol 2011; 34(6): 385–392. doi: 10.1016/j.gastrohep.2011.03.023.
53. Goldberg R, Irving PM. Toxicity and response to thiopurines in patients with inflammatory bowel disease. Exp Rev Gastroenterol Hepatol 2015; 9(7): 891–900. doi: 10.1586/17474124.2015.1039987.
54. De Ridder L, Van Dieren JM, Van Deverten HJH et al. Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Aliment Pharmacol Ther 2006; 23(8): 1137–1141. doi: 10.1111/j.1365-2036.2006.02853.x.
55. Bär F, Sina C, Fellermann K. Thiopurines in inflammatory bowel disease revisited. World J Gastroenterol 2013; 19(11): 1699–1706. doi: 10.3748/wjg.v19.i11.1699.
56. Kim MJ, Lee SY, Choe YH. Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease. Yonsei Med J 2014; 55(5): 1289–1296. doi: 10.3349/ymj.2014.55.5.1289.
57. Schwab M, Schäffeler E, Marx C et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12(6): 429–436. doi: 10.1097/00008571-200208000-00003.
58. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn‘s disease and severe myelosuppresion during azathioprine therapy. Gastroenterology 2000; 118(6): 1025–1030. doi: 10.1016/s0016-5085(00)70354-4.
59. Lennard L. TPMT in the treatement of Crohn‘s disease with azathioprine. Gut 2002; 51(2): 143–146. doi: 10.1136/gut.51.2.143.
60. Leipold G, Schütz E, Haas JP et al. Azathioprine-induced severe pancytopenia due to homozygous two-point mutation of the thiopurine methyltransferase gene in patient with juvenile HLA-B27_asociated spondylarthritis. Artritis Rheum 1997; 40(10): 1896–1898. doi: 10.1002/art.1780401026.
61. Dubinsky MC, Lamothe S, Ying Yang G et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterol 2000; 118(4): 705–713. doi: 10.1016/s0016-5085(00)70140-5.
62. Dubinsky CM. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2(9): 731–743. doi: 10.1016/s1542-3565(04)00344-1.
63. Kenedy NA, Ratigan E, Arnott IDR et al. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther 2013; 38(10): 1255–1266. doi: 10.1111/apt.12511.
64. Vernier-Massouille G, Cosnes J, Lemann M et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treted with azathioprine. Gut 2007; 56(10): 1404–1409. doi: 10.1136/gut.2006.114363.
65. Seiderer J, Zech CJ, Diebold J et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006; 18(5): 553–555. doi: 10.1097/00042737-200605000-00018.
66. Meyer L, Simian D, Lubascher J et al. Eventos adversos en la terapia farmacológica de la enfermedad inflamatoria intestinal. Rev Med Chile 2015; 143(1): 7–13. doi: 10.4067/S0034-98872015000100001.
67. Weersma RK, Peters FTM, Oostenburg LE et al. Increased incidence of azathioprine-induced pancreatitis in Crohn‘s disease compared with other diseases. Aliment Pharmacol Ther 2004; 20(8): 843–850. doi: 10.1111/j.1365-2036. 2004.02197.x.
68. Fanbing Z, Xiang G, Liang D et al. Prospective evaluation of pharmacogenomics and metabolite measurements upon azathioprine therapy in inflammatory bowel disease. Medicine 2016; 95(15): e3326. doi: 10.1097/MD. 0000000000003326.
69. Bermejo F, Lopez-Sanroman A, Taxonera C et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther 2008; 28(5): 623–628. doi: 10.1111/j.1365-2036.2008.03746.x.
70. Wilson A, Jansen LE, Rose RV et al. HLA-DQA1-HLA-DRB1 polymorfism is a major predictor of azathioprine-induced pancreatitis with inflammatory bowel disease. Aliment Pharmacol Ther 2017; 47(5): 615–620. doi: 10.1111/apt.14483.
71. Hindorf U, Johansson M, Eriksson A et al. Mercaptopurine treatement should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29(6): 654–661. doi: 10.1111/j.1365-2036.2008.03925.x.
72. Gallego-Gutiérrez S, Navas-Lopéz VM, Kolorz M et al. Successful mercaptopurine usage despite azathioprine-induced pancreatitis in paediatric Crohn‘s disease. J Crohns Colitis 2015; 9(8): 676–679. doi: 10.1093/ecco-jcc/jjv086.
73. Ledder OD, Lemberg DA, Ooi CY et al. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 57(5): 583–586. doi: 10.1097/MPG.0b013e31829f16fc.
74. Lees CW, Maan AK, Hansoti B et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27(3): 220–227. doi: 10.1111/j.1365-2036.2007.03570.x.
75. Schwab M, Klotz U. Pharmacokinetic considerations in the treatement of inflammatory bowel disease. Clin Pharmacokinet 2001; 40(10): 723–751. doi: 10.2165/00003088-200140100-00003.
76. Doménech E, Nos P, Papo M et al. 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol 2005; 40(1): 50–52. doi: 10.1080/00365520410009492.
77. Marinaki AM, Ansari A, Duley JA et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogen 2004; 14(3): 181–187. doi: 10.1097/00008571-200403000-00006.
78. Gearry RB, Roberts RL, Barclay ML et al. Lack of association between the ITP 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004; 14(11): 779–781. doi: 10.1097/00008571-200411000-00010.
79. Toruner M, Loftus EV, Harmsen WS et al. Risk factors for opportunistic infections in patietnts with inflammatory bowel disease. Gastroenterol 2008; 134(4): 929–936. doi: 10.1053/j.gastro.2008.01.012.
80. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based Consensus on the prevention, dia­gnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3(2): 47–91. doi: 10.1016/j.crohns.2009.02.010.
81. Kirchgesner J, Lemaitre M, Carrat F et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel disease. Gastroenterology 2018; 155(2): 337–346. doi: 10.1053/j.gastro.2018.04.012.
82. Seksik P, Cosnes J, Sokol H et al. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflamatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther 2009; 29(10): 1106–1113. doi: 10.1053/j.gastro.2018.04.012.
83. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn‘s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012; 107(9): 1409–1422. doi: 10.1038/ajg.2012.218.
84. Baldassano R, Colletti RB, Cucchiara S et al. Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: develop registry data. Gastro­enterology 2013; 144(5): S-11. doi: 10.1016/S1 873-9946(13)60016-1.
85. Veereman-Wauters G, de Ridder L, Veres G et al. Risk of infection and preventio in pediatric patients with IBD: ESPHGAN IBD Porto Group commentary. J Pediatr Gastroenterol Nutr 2012; 54(6): 830–837. doi: 10.1097/MPG.0b013e31824d1438.
86. Magro F, Abreu C. Immunisations in Crohn‘s disease: who? why? what? when? Best Pract Res Clin Gastroenterol 2014; 28(3): 485–496. doi: 10.1016/j.bpg.2014.04.007.
87. Khan N, Abbas AM, Lichtenstein GR et al. Risk of lymphoma in patients withulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013; 145(5): 1007–1015. doi: 10.1053/j.gastro.2013. 07.035.
88. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn‘s disease: benefits outweigh the risk of lym­homa. Gastroenterology 2000; 118(6): 1018––1024. doi: 10.1016/s0016-5085 (00) 70353-2.
89. Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a propective observational cohort study. Lancet 2009; 374(9701): 1617–1625. doi: 10.1016/S0140-6736(09)61302-7.
90. Kandiel A, Fraser AG, Korelitz BI et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54(8): 1121–1125. doi: 10.1136/gut.2004.049460.
91. Ashworth LA, Billet A, Mitchell P et al. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis 2012; 18(5): 838–843. doi: 10.1002/ibd.21844.
92. Joose ME, Aardoom MA, Kemos P et al. Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year propsective, multinational study from the paediatric IBD Porto group of ESPHGAN. Aliment Pharmacol Ther 2018; 48(5): 523–537. doi: 10.1111/apt.14893.
93. Kotlyar DS, Osterman MT, Diamond RH et al. A systemic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9(11): 36–41. doi: 10.1016/j.cgh.2010.09.016.
94. Chew C. FDA Drug Safety Communication: UPDATE on tumor necrosis factor (TNF) blockers and risk for pediatric malignancy. [online]. Dostupné z URL: https: //www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-update-tumor-necrosis-factor-tnf-blockers-and-risk-pediatric.
95. Dayhash GA, Loftus EV, Sandborn WJ et al. Ebstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122(1): 72–77. doi: 10.1053/gast.2002.30328.
96. Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010; 4(5): 511–522. doi: 10.1016/j.crohns.2010.05.006.
97. van Schaik FDM, van Oijen MGH, Smeets HM et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012; 61(2): 235–240. doi: 10.1136/gut.2011.237412.
98. Singh H, Nuget Z, Demers AA et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011; 141(5): 1612–1620. doi: 10.1053/j.gastro.2011.07.039.
99. O‘Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309(5743): 1871–1874. doi: 10.1126/science.1114233.